Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
2,149
Views
5
CrossRef citations to date
0
Altmetric
Research Papers

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer

Esraa A. Abdelsalama Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, EgyptCorrespondence[email protected] [email protected]
View further author information
,
Amer Ali Abd El-Hafeezb Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA;c Pharmacology and Experimental Oncology Unit, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, EgyptCorrespondence[email protected] [email protected]
View further author information
,
Wagdy M. Eldehnad Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt;e School of Biotechnology, Badr University in Cairo, Badr City, Cairo, EgyptView further author information
,
Mahmoud A. El Hassabf Department of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, EgyptView further author information
,
Hala Mohamed M. Marzoukb Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA;g Department of Biochemistry, Faculty of Medicine, Minia University, El-Minia, EgyptView further author information
,
Mahmoud M. Elaasserh The Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, EgyptView further author information
,
Nageh A. Abou Taleba Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, EgyptView further author information
,
Kamilia M. Amini Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, EgyptView further author information
,
Hatem A. Abdel-Azizj Department of Applied Organic Chemistry, National Research Centre, Dokki, Giza, EgyptView further author information
,
Pradipta Ghoshb Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA;k Department of Medicine, University of California San Diego, La Jolla, CA, USA;l Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA;m Veterans Affairs Medical Center, La Jolla, CA, USAView further author information
&
Sherif F. Hammada Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt;n PharmD Program and Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, EgyptCorrespondence[email protected]
View further author information
 show all
Pages 2265-2282 | Received 31 May 2022, Accepted 18 Jul 2022, Published online: 23 Aug 2022

References

  • Howard HA. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829–42.
  • Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605–44.
  • Wee P, Wang Z. “Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017;9:52.
  • Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.
  • Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 2010;584:2699–706.
  • Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104:1241–5.
  • Abdelsalam EA, Zaghary WA, Amin KM, et al. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors. Bioorg Chem 2019;89:102985.
  • Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 2009;22:128–33.
  • Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39.
  • Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013;13:663–73.
  • Koudelakova V, Kneblova M, Trojanec R, et al. Non-small cell lung cancer - genetic predictors. Biomed Pap 2013;157:125–36.
  • Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
  • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
  • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004;101:13306–11.
  • Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013;6:re6–re6.
  • Ko B, Paucar D, Halmos B. EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer Targets Ther 2017;8:147–59.
  • Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702–11.
  • Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924–32.
  • Jackson PA, Widen JC, Harki DA, Brummond KM. Covalent modifiers: a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via Hetero-Michael addition reactions. J Med Chem 2017;60:839–85.
  • Yun C-H, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci 2008;105:2070–5.
  • Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014;120:1145–54.
  • Ou S-H, Soo R. Dacomitinib in lung cancer: a ‘lost generation’ EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Dev Ther 2015;9:5641–53.
  • Camidge DR, Pao W, Sequist V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11:473–81.
  • Tan C-S, Kumarakulasinghe NB, Huang Y-Q, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer 2018;17:29.
  • Murtuza A, Bulbul A, Shen JP, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 2019;79:689–98.
  • Yu HA, Tian SK, Drilon AE, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015;1:982–4.
  • Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560–2.
  • Zhang Y-C, Zhou Q, Wu Y-L. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives. Cancer Lett 2019;459:240–7.
  • Montor WR, Salas AROSE ,de Melo FHM. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol Cancer 2018;17:55.
  • McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5:3–10.
  • Pennell NA, Lynch TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009;14:399–411.
  • Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol 2021;16:205–15.
  • Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008;5:521–30.
  • Sarkar S, Mazumdar A, Dash R, et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010;9:592–603.
  • Deng X, Tan X, An T, et al. Synthesis, characterization, and biological activity of a novel series of benzo[4,5]imidazo[2,1-b]thiazole derivatives as potential epidermal growth factor receptor inhibitors. Molecules 2019;24:682.
  • Mahmoud HK, Farghaly TA, Abdulwahab HG, et al. Novel 2-indolinone thiazole hybrids as sunitinib analogues: design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. Eur J Med Chem 2020;208:112752.
  • Amin KM, Barsoum FF, Awadallah FM, Mohamed NE. Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity. Eur J Med Chem 2016;123:191–201.
  • Faria JV, Vegi PF, Miguita AGC, et al. Recently reported biological activities of pyrazole compounds. Bioorg Med Chem 2017;25:5891–903.
  • El-Husseiny WM, El-Sayed MAA, Abdel-Aziz NI, et al. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study. J Enzyme Inhib Med Chem 2018;33:507–18.
  • Ahmed MF, Santali EY, El-Haggar R. Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. J Enzyme Inhib Med Chem 2021;36:307–18.
  • Alkamaly OM, Altwaijry N, Sabour R, Harras MF. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: synthesis and antitumor activity of novel pyrazoline derivatives. Arch Pharm 2021;354:2000351.
  • Viveka S, Shama DP, Nagaraja GK, et al. Design and synthesis of some new pyrazolyl-pyrazolines as potential anti-inflammatory, analgesic and antibacterial agents. Eur J Med Chem 2015;101:442–51.
  • Kaplancıklı ZA, Özdemir A, Turan-Zitouni G, et al. New pyrazoline derivatives and their antidepressant activity. Eur J Med Chem 2010;45:4383–7.
  • Beyhan N, Kocyigit-Kaymakcioglu B, Gümrü S, Aricioglu F. Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones. Arab J Chem 2017;10:S2073–S2081.
  • Bano S, Alam MS, Javed K, et al. Synthesis, biological evaluation and molecular docking of some substituted pyrazolines and isoxazolines as potential antimicrobial agents. Eur J Med Chem 2015;95:96–103.
  • Wang H-H, Qiu K-M, Cui H-E, et al. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents. Bioorg Med Chem 2013;21:448–55.
  • Lv P-C, Li D-D, Li Q-S, et al. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Bioorg Med Chem Lett 2011;21:5374–7.
  • Yuan J-W, Wang S-F, Luo Z-L, et al. Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents. Bioorg Med Chem Lett 2014;24:2324–8.
  • George RF, Samir EM, Abdelhamed MN, et al. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. Bioorg Chem 2019;83:186–97.
  • Mohamed TK, Batran RZ, Elseginy SA, et al. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorg Chem 2019;85:253–73.
  • Elzahabi HSA, Nossier ES, Alasfoury RA, et al. Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2022;37:1053–76.
  • Al-Warhi T, El Kerdawy AM, Said MA, et al. Novel 2-(5-Aryl-4,5-dihydropyrazol-1-yl)thiazol-4-one as EGFR inhibitors: synthesis, biological assessment and molecular docking insights. Drug Des Dev Ther 2022;16:1457–71.
  • Yousef RG, Ibrahim A, Khalifa MM, et al. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J Enzyme Inhib Med Chem 2022;37:1389–403.
  • Taghour MS, Elkady H, Eldehna WM, et al. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem 2022;37:1903–17.
  • Hagras M, Saleh MA, Ezz Eldin RR, et al. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J Enzyme Inhib Med Chem 2022;37:386–402.
  • Sivakumar PM, Prabhakar PK, Doble M. Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones. Med Chem Res 2011;20:482–92.
  • Sharifzadeh B, Mahmoodi NO, Mamaghani M, et al. Facile regioselective synthesis of novel bioactive thiazolyl-pyrazoline derivatives via a three-component reaction and their antimicrobial activity. Bioorg Med Chem Lett 2013;23:548–51.
  • Altıntop MD, Özdemir A, Turan-Zitouni G, et al. A novel series of thiazolyl–pyrazoline derivatives: synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity. Eur J Med Chem 2015;92:342–52.
  • Yao HC, Resnick P. Azo-hydrazone conversion. I. The Japp-Klingemann Reaction. J Am Chem Soc 1962;84:3514–7.
  • Thirunarayanan G, Thirumurthy K, Vanangamudi G, et al. Fly-ash : water catalyzed greener synthesis and insect antifeedant activities of some chalcones. Elixir Org Chem 2012;45:7898–905.
  • Narender T, Papi Reddy K. A simple and highly efficient method for the synthesis of chalcones by using borontrifluoride-etherate. Tetrahedron Lett 2007;48:3177–80.
  • Mubeen M, Kini SG, Pai KSR. Design, synthesis, antioxidant and anticancer activity of novel pyrazole derivatives. Der Pharm Chem 2015;7:215–23.
  • Fathi MAA, Abd El-Hafeez AA, Abdelhamid D, et al. “1,3,4-Oxadiazole/chalcone hybrids: design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. Bioorg Chem 2019;84:150–63.
  • Fathy Abdel-Wahab B, Sediek A, Ahmed Mohamed H, Elsayed Ahmed Awad G. Novel 2-pyrazolin-1-ylthiazoles as potential antimicrobial agents. Lett Drug Des Discov 2012;10:111–8.
  • Vignon C, Debeissat C, Georget M-T, et al. Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot. PLoS One 2013;8:e68425.
  • Abd El-Hafeez AA, Fujimura T, Kamei R, et al. A methoxyflavanone derivative from the Asian medicinal herb (Perilla frutescens) induces p53-mediated G2/M cell cycle arrest and apoptosis in A549 human lung adenocarcinoma. Cytotechnology 2018;70:899–912.
  • Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008;8:1555–72.
  • Scholz C, Knorr S, Hamacher K, Schmidt B. DOCKTITE—a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment. J Chem Inf Model 2015;55:398–406.
  • El Hassab MA, Ibrahim TM, Al-Rashood ST, et al. In silico identification of novel SARS-COV-2 2′-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches. J Enzyme Inhib Med Chem 2021;36:727–36.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.